X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Orladeyo (berotralstat), an inhibitor of plasma kallikrein, is the first and only oral therapy specifically designed to prevent hereditary angioedema attacks in adult and pediatric patients aged 12 and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pint Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2024
Details:
Orladeyo (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older.
Lead Product(s): Berotralstat Dihydrochloride
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
Argentina's regulatory body approved the drug product, Orladeyo® (berotralstat), a plasma kallikrein inhibitor, is the first and only oral therapy designed to prevent attacks of HAE in adult and pediatric patients 12 years and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
Orladeyo (berotralstat) is an oral, once-daily, plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023
Details:
Under the agreement, BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector® to deliver avoralstat directly to the back of the eye through the suprachoroidal space to treat patients with diabetic macular edema (DME).
Lead Product(s): Avoralstat
Therapeutic Area: Ophthalmology Product Name: BCX4161
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Clearside Biomedical
Deal Size: $82.5 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement November 06, 2023
Details:
BCX10013 as a potential best-in-class, once-daily, oral Factor D inhibitor for multiple complement-mediated diseases. It is being investigated for paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
Lead Product(s): BCX10013
Therapeutic Area: Genetic Disease Product Name: BCX10013
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
Orladeyo® (berotralstat) is the first and only oral therapy designed to prevent attacks of HAE in adult and pediatric patients 12 years and older. One capsule per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Under the collaboration, Er-Kim Pharmaceuticals will commercialize Orladeyo (berotralstat), the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older, in Turkey.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Erkim
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 19, 2023
Details:
Orladeyo® (berotralstat) is the first and only oral therapy designed to prevent attacks of HAE in adult and pediatric patients 12 years and older. One capsule per day works to prevent HAE attacks by decreasing the activity of plasma kallikrein.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pint Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
Orladeyo® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) by decreasing the activity of plasma kallikrein in adult and pediatric patients 12 years and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
